A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
This editorial by Lucas Grundmeier represents the views of the Register's editorial board. The new report “Miracle of Breath” from the Register’s Iowa columnist, Courtney Crowder, spans decades to ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor ...
In a bar, a poet meets the man behind the drug that saved his life — discovering how science, faith and chance created a ...
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of ...
Dr Uta Hill joins the Clinical Excellence in Respiratory Care speaker line-up to discuss adult cystic fibrosis services and ...
The agency has expanded the use of Alyftrek and Trikafta for treating patients with any genetic variant that results in production of CFTR proteins.
NEW YORK, March 24, 2026--(BUSINESS WIRE)--Cantor Fitzgerald Income Trust, Inc., a Maryland corporation (the "Company"), today announced the commencement of a proposed underwritten public offering of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results